Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-050719

Chief Financial Officer sold 25,000 shares at an average $138.52 ($3,462,926)

  • Chief Financial Officer acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
TOMSICEK MICHAEL JOHN Chief Financial Officer 2021-08-06 Option exercise +25,000 $17.75 $443,750 26,891 D
TOMSICEK MICHAEL JOHN Chief Financial Officer 2021-08-06 Sale −19,011 $138.22 $2,627,700 7,880 D
TOMSICEK MICHAEL JOHN Chief Financial Officer 2021-08-06 Sale −5,989 $139.46 $835,226 1,891 D
Derivatives
TOMSICEK MICHAEL JOHN Chief Financial Officer 2021-03-11 Option exercise · Stock Option (Right to Buy) −25,000 131,000 D
Open-market sales · 25,000 sh · avg $138.52 · $3,462,926
Loading xslF345X03/doc4.xml…